Breaking Finance News

AptarGroup (NYSE:ATR) target price raised to $83.00, reported today by Jefferies

AptarGroup (NYSE:ATR) had its target price raised to $83.00 by Jefferies in a report released 10/13/2016. The new target price indicates a possible upside of 0.10% based on the company's last stock close price.

Previously on Friday September 09, 2016, Robert W. Baird reported about AptarGroup (NYSE:ATR) raised the target price from $80.00 to $84.00. At the time, this indicated a possible upside of 0.07%.

Yesterday AptarGroup (NYSE:ATR) traded 0.00% even at $75.66. The company’s 50-day moving average is $77.82 and its 200-day moving average is $77.72. The last stock close price is down -2.66% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 231,252

See Chart Below

AptarGroup (NYSE:ATR)

AptarGroup has a 52 week low of $66.33 and a 52 week high of $81.50 with a P/E ratio of 24.56 The company’s market cap is currently $0.

About AptarGroup (NYSE:ATR)

AptarGroup, Inc. is a provider of a range of packaging, dispensing and sealing solutions, primarily for the beauty, personal care, home care, prescription drug, consumer healthcare, injectables, food and beverage markets. The Company has manufacturing facilities located in North America, Europe, Asia and South America. The Company's segments include Beauty + Home, Pharma and Food + Beverage. It offers various dispensing and sealing solutions. Its primary products are dispensing pumps, closures and aerosol valves. It also manufactures and sells elastomer primary packaging components, which include stoppers for infusion, antibiotic, lyophilization and diagnostic vials. The Company's elastomer components also include pre-filled syringe components, such as plungers, needle shields, tip caps and cartridges, as well as dropper bulbs and disposable syringe plungers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *